Lindbrook Capital, LLC Protagonist Therapeutics, Inc Transaction History

Lindbrook Capital, LLC

$1.06 Billion
Q1 2025

A detailed history of Lindbrook Capital, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Lindbrook Capital, LLC holds 143 shares of PTGX stock, worth $6,522. This represents 0.0% of its overall portfolio holdings.

Number of Shares

143

Previous 66 116.67%

Holding current value

$6,522

Previous $2,000 200.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 05, 2025	BUY	$35.09 - $59.76 $2,701 - $4,601	77 Added 116.67%	143 $6,000
Q4 2024 Feb 06, 2025	SELL	$38.51 - $48.43 $385 - $484	-10 Reduced 13.16%	66 $2,000
Q3 2024 Nov 01, 2024	BUY	$33.72 - $47.33 $910 - $1,277	27 Added 55.1%	76 $3,000
Q2 2024 Jul 31, 2024	SELL	$24.66 - $34.8 $3,057 - $4,315	-124 Reduced 71.68%	49 $1,000
Q1 2024 Apr 25, 2024	BUY	$21.79 - $32.15 $3,769 - $5,561	173 New	173 $5,000
Q2 2022 Aug 01, 2022	BUY	$7.06 - $25.52 $183 - $663	26 New	26 $0
Q4 2021 Jan 18, 2022	SELL	$17.63 - $37.1 $43,193 - $90,895	-2,450 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$12.95 - $49.69 $25,900 - $99,380	2,000 Added 444.44%	2,450 $43,000
Q2 2021 Jul 27, 2021	SELL	$25.57 - $44.88 $70,317 - $123,420	-2,750 Reduced 85.94%	450 $20,000
Q1 2021 Apr 28, 2021	BUY	$19.02 - $31.15 $38,040 - $62,300	2,000 Added 166.67%	3,200 $83,000
Q4 2020 Jan 27, 2021	BUY	$18.49 - $25.13 $18,490 - $25,130	1,000 Added 500.0%	1,200 $24,000
Q2 2020 Jul 27, 2020	SELL	$6.19 - $18.84 $8,047 - $24,492	-1,300 Reduced 86.67%	200 $4,000
Q1 2020 Apr 22, 2020	BUY	$5.4 - $9.22 $8,100 - $13,830	1,500 New	1,500 $11,000

Others Institutions Holding PTGX

# of Institutions

299

Shares Held

61.3M

Call Options Held

1.01M

Put Options Held

555K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.24B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account

Lindbrook Capital, LLC Protagonist Therapeutics, Inc Transaction History